RUNX2 and osteoporosis: Elevated expression of SOX5 has been evident in bone marrow-derived MSCs of postmenopausal osteoporosis patients and its overexpression inhibits the osteogenic differentiation of MSCs supported by reductions in ALP activity and osteoblast marker levels (Collagen I and Runx2) [27].